Pharmaceutical Industry Policy Institute
Priority Issues and Activities
1. research team
Based on the understanding and recognition of the actual situation of the pharmaceutical industry and the social role and importance it should play, the institute will establish research teams with the main themes of "drug discovery environment development," "utilization of health and medical data," and "value-based evaluation of pharmaceutical products" to conduct analysis and make proposals that will lead to medium- to long-term policies.
(1) Drug Discovery Environment Team
-
Understanding the actual status of Japan's ability to create new drugs
To understand the actual status of new drug creation capability through analysis of the WRA Top 100/300 by Japanese product ratio, analysis by modality, analysis of collaboration, analysis of unmet medical needs and new drug development status, and continuous compilation and analysis of NME review items and periods in Japan, the U.S., and Europe, etc., which have been conducted by the NIHS as fixed-point observations.
-
Research on the development and enhancement of the drug discovery environment
Research will be conducted on the improvement and strengthening of Japan's drug discovery environment, focusing on current issues, including the co-creation environment and the maintenance and strengthening of drug discovery capabilities, which have been the focus of ongoing research by the Policy Research Institute.
In addition, through the above-mentioned research, we will identify issues for the establishment of a drug discovery ecosystem, which the Pharmaceutical Manufacturers Association of Japan (PMAJ) has been advocating, and disseminate necessary information in cooperation with related stakeholders.
(2) Health and Medical Data Team
-
Evaluation of Japan's health and medical data utilization system and study of its direction
The contents of the revised Next Generation Medical Infrastructure Act and other systems for the utilization of health and medical data in Japan will be evaluated, the actual status of utilization will be ascertained, and the direction of these systems will be studied.
In addition, we will make international comparisons by understanding similar systems and the actual status of utilization in other countries, point out areas for improvement in Japan's system, and study the direction of international data utilization. -
Examination of individual issues related to the promotion of the utilization of health and medical data in the pharmaceutical industry
From the perspective of promoting the utilization of health and medical data in the pharmaceutical industry, research individual issues such as information distribution, standardization, personal information protection, and public literacy, and disseminate necessary information in cooperation with relevant stakeholders.
(3) Drug Value Evaluation Team
-
Research on the ideal drug price system in which the value of pharmaceutical products is evaluated
Through research on the significance and actual conditions of various systems, such as drug price systems in other countries and price adjustment mechanisms in cost-effectiveness evaluation systems, we will understand and evaluate the trends in the Japanese drug market and the actual conditions of revisions to the NHI drug price system. Depending on the results of our research, we will disseminate necessary information in cooperation with related stakeholders.
-
Grasping and evaluating the actual situation of the NHI drug price system in which innovation is appropriately evaluated
Through research and study of Japan's NHI drug price system, conduct research on the ideal direction of the NHI drug price system in which innovation is appropriately evaluated.
2. data office
The team will conduct research and analysis activities that contribute to the promotion of various activities of the Pharmaceutical Manufacturers Association of Japan (PMAJ) and provide data that is effective in improving the understanding of the industry. In addition, the team will promote improvements, including streamlining the operation of the industry survey database (DB) and data book currently in operation, and reconstruct the data provided and the provision system.
1) Research work
-
Development of various fixed-point data
Survey on the general situation of activities, update and web publication of DATA BOOK 2025, survey on R&D taxation performance, development of basic data on the market and profit structure of the pharmaceutical industry, including indicators on the economic contribution of pharmaceuticals, operation, maintenance and updating of the "Industry Research Database (DB).
-
Enhancement of industry survey function through collaboration with academia
Collaboration with Meiji Pharmaceutical University on unmet medical needs